(Reuters) -U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s single-dose COVID-19 vaccine after six recipients developed a rare disorder involving blood clots.
The U.S. Centers for Disease Control and Prevention will hold an advisory meeting on Wednesday to review the cases.
All the six recipients were women between the ages of 18 and 48. One woman died and a second in Nebraska has been hospitalized in critical condition, the New York Times reported, citing officials. (nyti.ms/3g70oLK)
The CDC and the U.S. Food and Drug Administration said in a joint statement that the adverse events appear to be extremely rare right now.
As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States.
The company’s shares were down 3% before the opening bell.
The move from the U.S. regulators comes less than a week after Europe’s drugs regulator said it was reviewing rare blood clots in four people in the United States who received the shot.
Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel and Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.
免責事項：本記事で述べられている見解は著者の見解のみであり、Followmeの公式見解を反映するものではありません。Followmeは、提供された情報の正確性、完全性、信頼性について一切責任を負いません。また、書面で明示的に記載されている場合を除き、本記事の内容に基づいて行われたいかなる行動についても責任を負いません。
古いコメントはありません。ソファをつかむ最初のものになりましょう。